JOHNSON & JOHNSON is 138.4x more valuable than Tango Therapeutics, Inc. by market capitalization ($573.98 B vs $4.15 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TNGX | JNJ |
|---|---|---|
| Market cap | $4.15 B | $573.98 B |
| US-listed rank | #1540 | #20 |
| Revenue (latest FY) | $62.38M | $94.19B |
| Net income (latest FY) | -$101.60M | $26.80B |
| Net margin | -162.9% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 382 | 984 |
JOHNSON & JOHNSON is 138.4x more valuable than Tango Therapeutics, Inc. by market capitalization ($573.98 B vs $4.15 B).
In their latest fiscal years, Tango Therapeutics, Inc. reported $62.38M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Tango Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.